REMOVAL OF MYELOTOXICITY FROM ANTILYMPHOCYTIC SERA
- 1 February 1979
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 27 (2) , 106-109
- https://doi.org/10.1097/00007890-197902000-00008
Abstract
SUMMARY Antilymphocyte sera (ALS) were prepared by different methods and examined for their myelotoxicity by bone marrow colony-forming assay, both before and after absorption with B cell antigens. The results show that myelotoxicity can readily be removed from some, but not all, ALS. The source of antigen and the immunisation protocol used determine the degree of myelotoxicity and hence the number of absorptions required. Non-myelotoxic ALS may be suitable for the prevention of graft-versus-host disease (GVHD) by in vitro treatment of bone marrow before transplantation.This publication has 5 references indexed in Scilit:
- Immunoabsorbents prepared from cell membrane antigens: Efficiency of incorporation and shedding of protein during useJournal of Immunological Methods, 1978
- ANTISERA WITH SPECIFICITY FOR HUMAN T LYMPHOCYTESTransplantation, 1977
- Cross-reacting anti-monkey lymphocyte antisera: A simplified immunofluorescence approach for detecting human T and B lymphocytesJournal of Surgical Research, 1977
- PREPARATION OF ANTISERA WITH SPECIFICITY FOR HUMAN T LYMPHOCYTESTransplantation, 1977
- PREPARATION AND CHARACTERIZATION OF ANTITHYMOCYTE SERUM AND GLOBULIN WITHOUT STEM CELL ACTIVITYTransplantation, 1976